DDInter93 DDInter915
Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Anagrelide {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Anagrelide {u} (Compound) upregulates {v} (Gene) MSRA
MSRA {u} (Gene) is upregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Anagrelide {u} (Compound) downregulates {v} (Gene) HIF1A
HIF1A {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Anagrelide {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is regulated by {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Theophylline
Theophylline {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Anagrelide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Isoprenaline
Isoprenaline {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Anagrelide {u} may lead to a major life threatening interaction when taken with {v} Isoprenaline
Isoprenaline {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Anagrelide (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Indacaterol (Compound)
Anagrelide (Compound) upregulates MSRA (Gene) and MSRA (Gene) is upregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Anagrelide (Compound) downregulates HIF1A (Gene) and HIF1A (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Anagrelide (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is regulated by UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Indacaterol (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Indacaterol (Compound)
Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)